Skip to main content

Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

The pharma monster has offered five of its ophthalmic medications to eye treatment organization Harrow for a one-time frame installment of $130 million, or more extra achievement installments of $45 million. The deal incorporates waterfall medical procedure recuperation eye drops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, irritation eye drops Maxidex and the injectable Triesence. The arrangement makes Harrow famous into "an administrative role in the U.S. ophthalmic drugs market," Imprint L. Baum, Harrow's Chief and executive, said in an assertion. "We know these items quite well and have long appreciated and respected them for the worth they have conveyed to great many U.S. eyecare experts and a huge number of their patients," Baum added. The arrangement will probably close during the main quarter of 2023. A while later, Novartis will in any case possess the items beyond the U.S. U.S. Novartis "stays focused on patients by supporting admittance to significant drugs for eye illnesses and conditions with our ongoing showcased items and future pipeline," an organization representative said in a messaged proclamation to Savage Pharma. Last month, Bloomberg announced that Novartis was thinking about selling its ophthalmology and respiratory sickness organizations, refering to individuals acquainted with the matter. Those two areas are excluded from the five-center helpful regions that the organization's President, Vas Narasimhan, M.D., focused on for the organization's future. At that point, the worth of the ophthalmology establishment was weighed at about $5 billion, individuals allegedly told Bloomberg. The arrangements were said to occur one year from now, if by any stretch of the imagination, as the organization completes its arranged Sandoz detachment. The deal is Novartis' most recent move to scale back in ophthalmology. In 2019, the Swiss pharma monster veered off its eye-care unit, Alcon, following eight years of proprietorship. The 2011 consolidation among Alcon and Novartis was the consequence of a three-year quest for the eye expert by Novartis. Yet, slacking deals ultimately prompted the split so Novartis could "center our capital and energy around building our center prescriptions business," Narasimhan said at that point.

Comments

Popular posts from this blog

Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025) The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries . 🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound. 1. The Core Dispute At the heart of this litigation is Indian Patent No. 262697 . Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active p...
Litigation Update: Dr. Reddy's vs. Novo Nordisk (Semaglutide) Litigation Update • December 12, 2025 Delhi High Court Clears Dr. Reddy's for Semaglutide Exports: Refuses Novo Nordisk Stay In a significant development for the Indian pharmaceutical sector, the Delhi High Court (Division Bench) has today refused to stay a Single Judge's order permitting Dr. Reddy’s Laboratories (DRL) to manufacture and export Semaglutide. This ruling comes as a setback for Danish pharma giant Novo Nordisk , the patent holder of the blockbuster drugs Ozempic and Wegovy , which had sought to completely block DRL from manufacturing the drug in India. ⚖️ The Verdict at a Glance The Decision: The Division Bench (Justices C. Hari Shankar & O.P. Shukla) upheld the Single Judge's interim order. The Winner (Today): Dr. Reddy’s Laborator...